3/20
08:44 am
atr
AptarGroup (ATR) was upgraded by Wells Fargo & Company from "equal weight" to "overweight". They now have a $144.00 price target on the stock.
Low
Report
AptarGroup (ATR) was upgraded by Wells Fargo & Company from "equal weight" to "overweight". They now have a $144.00 price target on the stock.
3/19
05:32 pm
atr
Aptar's Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA-051 Nasal Spray [Yahoo! Finance]
Low
Report
Aptar's Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA-051 Nasal Spray [Yahoo! Finance]
3/19
05:00 pm
atr
Aptar’s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA-051 Nasal Spray
Low
Report
Aptar’s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA-051 Nasal Spray
3/18
08:01 am
atr
New Strong Sell Stocks for March 18th [Yahoo! Finance]
Medium
Report
New Strong Sell Stocks for March 18th [Yahoo! Finance]
3/17
05:34 pm
atr
Aptar Announces Gael Touya as its Next Chief Executive Officer; Stephan B. Tanda to Retire by the End of the Year [Yahoo! Finance]
Medium
Report
Aptar Announces Gael Touya as its Next Chief Executive Officer; Stephan B. Tanda to Retire by the End of the Year [Yahoo! Finance]
3/17
05:00 pm
atr
Aptar Announces Gael Touya as its Next Chief Executive Officer; Stephan B. Tanda to Retire by the End of the Year
Medium
Report
Aptar Announces Gael Touya as its Next Chief Executive Officer; Stephan B. Tanda to Retire by the End of the Year
3/16
09:23 pm
atr
A Fresh Look At AptarGroup (ATR) Valuation After Recent Share Price Weakness [Yahoo! Finance]
Low
Report
A Fresh Look At AptarGroup (ATR) Valuation After Recent Share Price Weakness [Yahoo! Finance]
3/16
05:20 pm
atr
Aptar's Intranasal Delivery System Used in Phase II Clinical Study for Investigational SPONTAN® Nasal Spray [Yahoo! Finance]
Low
Report
Aptar's Intranasal Delivery System Used in Phase II Clinical Study for Investigational SPONTAN® Nasal Spray [Yahoo! Finance]
3/16
05:00 pm
atr
Aptar’s Intranasal Delivery System Used in Phase II Clinical Study for Investigational SPONTAN® Nasal Spray
Low
Report
Aptar’s Intranasal Delivery System Used in Phase II Clinical Study for Investigational SPONTAN® Nasal Spray
3/9
04:29 pm
atr
New Strong Sell Stocks for March 9th [Yahoo! Finance Canada]
Low
Report
New Strong Sell Stocks for March 9th [Yahoo! Finance Canada]
2/19
07:03 am
atr
Pharmaceutical Packaging Market Trends and Growth Projections to 2030 Featuring Profiles of AptarGroup, Amcor, SGD Pharma, West Pharmaceutical Services, SCHOTT Pharma and Other Key Players [Yahoo! Finance]
Low
Report
Pharmaceutical Packaging Market Trends and Growth Projections to 2030 Featuring Profiles of AptarGroup, Amcor, SGD Pharma, West Pharmaceutical Services, SCHOTT Pharma and Other Key Players [Yahoo! Finance]
2/18
05:00 pm
atr
Aptar to Participate in Upcoming Investor Conferences
Low
Report
Aptar to Participate in Upcoming Investor Conferences
2/10
06:28 am
atr
AptarGroup, Inc.'s (NYSE:ATR) Intrinsic Value Is Potentially 58% Above Its Share Price [Yahoo! Finance]
Low
Report
AptarGroup, Inc.'s (NYSE:ATR) Intrinsic Value Is Potentially 58% Above Its Share Price [Yahoo! Finance]
2/9
11:51 pm
atr
A Look At AptarGroup (ATR) Valuation As Earnings Guidance And New US$600 Million Buyback Draw Interest [Yahoo! Finance]
Low
Report
A Look At AptarGroup (ATR) Valuation As Earnings Guidance And New US$600 Million Buyback Draw Interest [Yahoo! Finance]
2/9
10:05 am
atr
AptarGroup (NYSE:ATR) was given a new $156.00 price target on by analysts at Robert W. Baird.
Low
Report
AptarGroup (NYSE:ATR) was given a new $156.00 price target on by analysts at Robert W. Baird.
2/6
05:56 pm
atr
AptarGroup Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
AptarGroup Q4 Earnings Call Highlights [Yahoo! Finance]
2/6
04:17 pm
atr
AptarGroup Inc (ATR) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Margin ... [Yahoo! Finance]
Medium
Report
AptarGroup Inc (ATR) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Margin ... [Yahoo! Finance]
2/6
03:50 pm
atr
AptarGroup outlines 2026 margin improvement and targets 7%–11% long-term pharma core sales growth amid emergency medicine headwinds [Seeking Alpha]
Low
Report
AptarGroup outlines 2026 margin improvement and targets 7%–11% long-term pharma core sales growth amid emergency medicine headwinds [Seeking Alpha]
2/5
07:27 pm
atr
AptarGroup (ATR) Q4 Earnings and Revenues Surpass Estimates [Yahoo! Finance]
Medium
Report
AptarGroup (ATR) Q4 Earnings and Revenues Surpass Estimates [Yahoo! Finance]
2/5
05:36 pm
atr
AptarGroup: Q4 Earnings Snapshot [Yahoo! Finance]
Medium
Report
AptarGroup: Q4 Earnings Snapshot [Yahoo! Finance]
2/5
05:00 pm
atr
Aptar Reports Fourth Quarter and Annual 2025 Results
Medium
Report
Aptar Reports Fourth Quarter and Annual 2025 Results
1/22
05:00 pm
atr
Aptar Declares Quarterly Dividend and Announces 2026 Annual Meeting Details
Low
Report
Aptar Declares Quarterly Dividend and Announces 2026 Annual Meeting Details
1/21
05:00 pm
atr
Aptar Again Recognized with Prestigious ‘A’ Score on the CDP Climate Change Assessment
Low
Report
Aptar Again Recognized with Prestigious ‘A’ Score on the CDP Climate Change Assessment
1/13
05:21 pm
atr
Aptar's Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate [Yahoo! Finance]
Medium
Report
Aptar's Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate [Yahoo! Finance]
1/13
05:00 pm
atr
Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate
Low
Report
Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate